Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Office Based Vergence and Accommodative Therapy and Intermittent Exotropia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03321838
Recruitment Status : Unknown
Verified June 2018 by Xiang Chen, Sun Yat-sen University.
Recruitment status was:  Active, not recruiting
First Posted : October 26, 2017
Last Update Posted : June 28, 2018
Sponsor:
Information provided by (Responsible Party):
Xiang Chen, Sun Yat-sen University

Brief Summary:
This pilot study is designed specifically to determine the short-term effect of OBVAT on intermittent exotropia in terms of 4 key areas (Standardizing reported outcomes of surgery for intermittent exotropia): control score, alignment, near stereoacuity and quality of life score. Result of this pilot study will be used to determine whether a full-scale RCT should be conducted to evaluate the short and long term effectiveness of OBVAT.

Condition or disease Intervention/treatment Phase
Intermittent Exotropia Behavioral: accommodative/vergence therapy Not Applicable

Detailed Description:

All enrolled px received 16-20 sessions of OBVAT, 60 minutes per visit, one time per week; Home reinforcement, 15 minutes each time, five times per week.

  1. Primary outcome measure: A. Change in the office based intermittent exotropia control score
  2. Secondary outcome measures A. Change in Look And Cover, then Ten seconds of Observation Scale for Exotropia (LACTOSE) B. Change in Newcastle Control Score (NCS) C. Change in Chinese intermittent exotropia questionnaire (CIXTQ) D. Change in near stereopsis by Preschool randot near stereoacuity E. Change in size of distant deviation angle by prism alternating cover test F. Change in size of near deviation angle by prism alternating cover test

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Office Based Vergence and Accommodative Therapy as Treatment of Intermittent Exotropia
Actual Study Start Date : November 1, 2017
Actual Primary Completion Date : January 31, 2018
Estimated Study Completion Date : December 30, 2018

Arm Intervention/treatment
Experimental: Accommodative/vergence therapy
Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
Behavioral: accommodative/vergence therapy
Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.




Primary Outcome Measures :
  1. Office based intermittent exotropia control score [ Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL) ]
    Office based intermittent exotropia control score is an office based score to assess the control of intermittent exotropia. Minimum score is 0 (best score, phoria) and Maximum score is 5(worst score, constant tropia). Change in Office based intermittent exotropia control score after 14 weeks of vision therapy


Secondary Outcome Measures :
  1. Look And Cover, then Ten seconds of Observation Scale for Exotropia(LACTOSE) [ Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL) ]
    Look And Cover, then Ten seconds of Observation Scale for Exotropia (LACTOSE) is an office based score to assess the control of intermittent exotropia. Minimum score is 0 (best score, phoria) and Maximum score is 4(worst score, constant tropia). Change in score after 14 weeks of vision therapy.

  2. Newcastle Control Score [ Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL) ]
    Newcastle Control Score is an office based and home based score to assess the control of intermittent exotropia. Minimum score is 0 (best score) and Maximum score is 6(worst score). Change in score after 14 weeks of vision therapy.Change in score after 14 weeks of vision therapy.

  3. Chinese intermittent exotropia questionnaire [ Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL) ]
    Change in Chinese intermittent exotropia questionnaire after 14 weeks of vision therapy.

  4. Preschool randot near stereoacuity [ Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL) ]
    Change in near stereopsis by Preschool randot near stereoacuity after 14 weeks of vision therapy.

  5. deviation angle [ Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL) ]
    Change in size of distant deviation angle by prism alternating cover test after 14 weeks of vision therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 8 to 18 years old
  2. deviation meeting all of the following criteria: A. intermittent or constant exotropia at distance (mean of 3 baseline assessments of distance control> or = Grade 2) B. intermittent exotropia at near (at least 1 of 3 assessments of near control at the baseline visit Grade 2-4) C. distance and near exodeviation both between 15 to 35 prism diopters (PD) measured by prism and alternate cover test (PACT); D. near deviation not exceeding the distance deviation by >10PD by PACT (i.e., convergence insufficiency type IXT excluded)
  3. cycloplegic objective refraction spherical equivalent (SE) refractive error between -6.00 diopters (D)and +1.00 D inclusive in either eye
  4. Patients must be wearing the updated refractive correction (spectacles or contact lenses) for at least 1 week if refractive error (based on cycloplegic refraction performed within 6 months) meets any of the following:

    A. Myopia >-0.50 D spherical equivalent in either eye B. Anisometropia >1.00 D spherical equivalent C. Astigmatism in either eye >1.50 D

  5. Refractive correction must meet the following guidelines:

    A. Anisometropia spherical equivalent must be within 0.25 D of the full anisometropic difference B. Astigmatism cylinder must be within 0.25 D of full correction and axis must be within 5 degree C. For hyperopia and myopia, the spherical component can be reduced by investigator discretion provided reduction is symmetrical and results in residual (i.e., uncorrected) spherical equivalent refractive error that does not exceed +1.50 D spherical equivalent hyperopia or -0.50 D spherical equivalent myopia

  6. Gestational age >34 weeks
  7. Birth weight >1500 g
  8. No previous surgical or nonsurgical treatment for IXT other than single vision refractive correction (e.g. PALs, Bifocals, patching, or deliberate over-minus with spectacles more than 0.50 D)
  9. No vision therapy or orthoptics for any reason within the last year
  10. No prior strabismus surgery or botulinum injection, intraocular surgery, or refractive surgery
  11. No strabismus surgery planned
  12. vision correctable to at least 20/25 or better at distance and near in each eye.
  13. Px needs to have a computer at home which can connect to internet

Exclusion Criteria:

  1. Patient with nystagmus, restrictive or paretic strabismus
  2. Patient with amblyopia, which is defined as >or = 0.2 logarithm of the minimum angle of resolution units of interocular difference and > or = 0.3 logarithm of the minimum angle of resolution units in one eye ( Variability of stereoacuity in intermittent exotropia)
  3. Regular use of any ocular or systemic medications known to affect accommodation or vergence system, such as atropine, pirenzepine, and anti-epileptic medications in recent 3 months;
  4. developmental disability, attention deficit hyperactivity disorder(ADHD), or learning disability diagnosis in children that in the investigator's discretion would interfere with office-based treatment;
  5. Relocation anticipated for 2 years;
  6. Significant ocular or neurologic disorders (e.g. cerebral palsy) other than strabismus
  7. Vertical deviation greater than 1 pd in cover test
  8. Household member already in the study.
  9. Any eye care professional, ophthalmic technician, medical student, or optometry student

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03321838


Locations
Layout table for location information
China, Guangdong
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 510000
Sponsors and Collaborators
Sun Yat-sen University
Investigators
Layout table for investigator information
Study Director: Chen xiang associate chief physician
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Xiang Chen, Associate clinical professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03321838    
Other Study ID Numbers: XT1
First Posted: October 26, 2017    Key Record Dates
Last Update Posted: June 28, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Exotropia
Strabismus
Ocular Motility Disorders
Cranial Nerve Diseases
Nervous System Diseases
Eye Diseases